Roberto Mina, MD

an associate professor at the Winship Cancer Institute of Emory University

Articles by Roberto Mina, MD

How Teclistamab Is Rewriting Second-Line Myeloma Care: Roberto Mina, MD

March 12th 2026

MajesTEC-9 supports moving teclistamab earlier in myeloma treatment, with robust PFS and OS gains over standard care in the second-line setting, notes Roberto Mina, MD.

Teclistamab's Growing Case for Earlier Use in Myeloma: Roberto Mina, MD

ByMaggie L. Shaw,Roberto Mina, MD

March 9th 2026

Roberto Mina, MD, details how in the MajesTEC-9 trial, teclistamab monotherapy boosted PFS and OS in relapsed/refractory multiple myeloma, challenging standardized care.

Roberto Mina, MD, Winship Cancer Institute of Emory University

Teclistamab Transforms Early Myeloma Care: Roberto Mina, MD

ByMaggie L. Shaw,Roberto Mina, MD

January 23rd 2026

The results of the phase 3 MajesTEC-9 trial showcase teclistamab's efficacy for patients with relapsed/refractory multiple myeloma, explained Roberto Mina, MD.

Roberto Mina, MD

Articles by Roberto Mina, MD

How Teclistamab Is Rewriting Second-Line Myeloma Care: Roberto Mina, MD

Teclistamab's Growing Case for Earlier Use in Myeloma: Roberto Mina, MD

Teclistamab Transforms Early Myeloma Care: Roberto Mina, MD

Latest Updated Articles

Trending on AJMC

Walcker Named President of Cardinal’s The Specialty Alliance, With Strengths in GI, Urology

Oral COVID-19 PEP May Benefit High-Risk Groups More Than General Public: Peter J. Hotez, MD

Ontada Analysis Finds GLP-1 RA Use Linked to Improved Survival in Patients With Cancer

Orexin Agonist Shows Promise for Treating Narcolepsy, Hypersomnia: Richard Bogan, MD

Study Finds Flaw in Method for Key Oncology Value-Based Care Model